Under Nasdaq’s listing rules, the Company has 60 calendar days from receipt of the notice to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an ...

To access the live webcast of the conference call, please go to the investor relations section of Lincoln’s website at Participants may also register via teleconference at: Q1 2026 Lincoln ...

Proxy Voting Information Registered shareholders and beneficial shareholders who have already submitted their proxy or voting instruction form do not need to resubmit them, as the ...

Sysco Corporation (NYSE:SYY) today announced that its Board of Directors declared a quarterly cash dividend of $0.55 per share, representing a $0.01 increase from the prior quarterly dividend of $0.54 ...

You are invited to join a live webcast of the conference call by visiting the "Investors Relations" section of the TTEC website at www.ttec.com. If you are unable to participate during the live ...

Following the presentation on April 19, 2026 from 2:00–5:00 PM PT, the poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of ...

Value Line, Inc. (NASDAQ – VALU) announced today that its Board of Directors has just raised its quarterly dividend, which will be $0.35 per common share ($1.40 annualized). The new higher cash ...

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based ...

- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients ...

In preclinical studies, XTX601 demonstrated the potential to achieve a wide therapeutic index. XTX601 demonstrated protease-dependent activation and tumor cell killing in high- and low-expression ...

The appointment reflects New Era’s continued expansion of its leadership team following the recent appointment of Ted Warner as Chief Financial Officer. Mr. Casazza will help connect corporate ...